ClinicalTrials.gg
Not yet recruitingNCT06319326Updated Mar 20, 2024

Intestinal Perfusion After Feeding in Preterm and Term Infants

An observational study in Premature and Necrotizing Enterocolitis, sponsored by The Hospital for Sick Children. Not yet recruiting at 1 site in China. Open to participants aged Up to 4 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-20.

Sponsored by The Hospital for Sick Children · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
Up to 4 Weeks
Sex
All
01

Study summary

This is a pilot exploratory observational prospective cohort phase I study. In this study, we will gather preliminary data to evaluate (i) the magnitude of changes in blood flow in the bowel before and after feeding and (ii) the differences between preterm and term infants.

Read the detailed description

Necrotizing enterocolitis (NEC) is the most devastating intestinal disease which remains a major unsolved clinical challenge in neonatology. NEC is predominantly a disease of preterm or extremely preterm infants. NEC results in high mortality, neurodevelopmental impairment, intestinal failure, and reduced quality of life.

Prematurity and enteral feeding are two of the most important risk factors for NEC. More than 90% of infants with NEC have been enterally fed, suggesting that feeding is an important priming step in making the intestine vulnerable to NEC. Absorption of nutrients is energy-consuming and results in an increased oxygen demand after feeding, followed by an increase in intestinal blood flow above baseline (known as postprandial hyperemia). Our preclinical studies have shown an intriguing discovery, that prematurity is associated with a remarkably reduced intestinal response to feeding, which predisposes the intestine to NEC.

However, there is lack of reliable clinical evidence to compare the magnitude of difference in postprandial intestinal blood flow in human preterm versus term infants. If preterm infants do in fact demonstrate a diminished intestinal blood flow response to feeding, this will shed light on the need for interventions in the feeding protocol of this vulnerable population to prevent the development of NEC.

This study is a phase I exploratory prospective cohort study. We will gather preliminary data to evaluate (i) the magnitude of changes in blood flow in the bowel before and after feeding and (ii) the differences between preterm and term infants.

In a cohort of 20 patients (10 preterm, 10 term), we will evaluate feeding-related perfusion of the superior mesenteric artery and bowel wall immediately before and 60-minutes after feeding.

02

Conditions studied

  • Premature
  • Necrotizing Enterocolitis

Keywords

  • intestinal perfusion
  • postprandial intestinal perfusion
  • Color Doppler abdominal ultrasound
03

In context

Premature Birth

2,550 studies on the registry are indexed under Premature Birth; 500 are open to participants now.

This study's planned enrollment of 20 is below the median of 120 across 806 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 578 studies on the registry; 83 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 4 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of 2 cohorts:

  • Preterm infants (≤33 weeks gestational age at birth) of any birth weight receiving full bolus enteral feeding.
  • Term infants of any birth weight aged 1-4 weeks.

The sources of preterm infants are level III/IV neonatal intensive care units at Xiamen Children's Hospital and the Hospital for Sick Children. The source of the cohort of term infants will be Level II neonatal ward at Children's Hospital of Fudan University (Xiamen Branch), Xiamen Children's Hospital and the Hospital for Sick Children.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Preterm infants (≤33 weeks gestational age) of any birth weight receiving full bolus enteral feeding.

Exclusion criteria

Exclusion Criteria:

  • Neonates receiving bolus enteral feeds lasting >30 minutes or continuous enteral feeds will be excluded to avoid overlapping or close timing between pre- and post-prandial intestinal perfusion measurements.
  • Large patent ductus arteriosus (PDA)
  • Major congenital malformations
  • Suspected genetic syndrome
  • Ssuspected or confirmed infection
  • Fraction of inspired oxygen of ≥0.60 at enrollment
  • Confirmed diagnosis of necrotizing enterocolitis diagnosis. NEC will be diagnosed when at least two of the following clinical signs and one radiological sign will be present: (i) Clinical signs (1. abdominal distension; 2. abdominal tenderness; 3. abdominal discoloration; 4. blood in stool). (ii) Radiological signs (1. Pneumoperitoneum; 2. pneumatosis; 3. portal venous gas).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Preterm infants

    Preterm infants (≤33 weeks gestational age) of any birth weight receiving full bolus enteral feeding, aged 1-4 weeks.

    Other: Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.

  • Term infants

    Term infants of any birth weight aged 1-4 weeks.

    Other: Evaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.

Interventions

  • OtherEvaluation of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding.

    This is an observation study involving measurement of intestinal perfusion with color Doppler abdominal ultrasound before and after feeding. No intervention is given to study participants.

    Also known as: No intervention.

06

What researchers measure

Primary outcomes

  1. Time-averaged mean velocity of the superior mesenteric artery

    Abdominal ultrasound is used to measure the percent change in time-averaged mean velocity (TAMV) of the superior mesenteric artery (SMA) between pre and post-prandial assessments.

    Time frame: Measured immediately before and 60 minutes after feeding

Secondary outcomes

  1. Bowel wall perfusion

    Color Doppler abdominal ultrasound is used to measure changes in peripheral perfusion of the bowel wall pre- and post-prandially.

    Time frame: Measured immediately before and 60 minutes after feeding

07

Study locations

1 site
  • Children's Hospital of Fudan University (Xiamen Branch)
    Xiamen, Fujian 361000, China
08

References and documents

Publications

  • Chen Y, Koike Y, Chi L, Ahmed A, Miyake H, Li B, Lee C, Delgado-Olguin P, Pierro A. Formula feeding and immature gut microcirculation promote intestinal hypoxia, leading to necrotizing enterocolitis. Dis Model Mech. 2019 Dec 9;12(12):dmm040998. doi: 10.1242/dmm.040998. PubMed 31704804 ↗
  • Chen Y, Koike Y, Miyake H, Li B, Lee C, Hock A, Zani A, Pierro A. Formula feeding and systemic hypoxia synergistically induce intestinal hypoxia in experimental necrotizing enterocolitis. Pediatr Surg Int. 2016 Dec;32(12):1115-1119. doi: 10.1007/s00383-016-3997-8. Epub 2016 Nov 4. PubMed 27815640 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Jun 2024, 2 months later.

Of 372 non-industry observational studies under Premature Birth, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 63. This study's planned 2 months is below that.

Counting every sponsor, half of 387 studies reached it within 35 months; a quarter within 18 and three quarters within 61.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Mar 20, 2024
StartEst.
Apr 2, 2024
Primary completionEst.
Jun 30, 2024
CompletionEst.
Aug 31, 2024
Last update
Mar 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06319326
Collaborators
Xiamen Children's Hospital
Responsible party
Agostino Pierro (Dr, The Hospital for Sick Children) — Principal investigator
First posted
Mar 20, 2024
Start date
Apr 2, 2024 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Mar 20, 2024

Study contacts

Agostino Pierro, OBE, MD, FRCS, FAAP
Contact
agostino.pierro@sickkids.ca
4168137654 ext. 309350
Niloofar Ganji, BSc, MSc
Contact
niloofar.ganji@sickkids.ca
6478702781

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion